
JORDAN, M R, et al.

Abstract
The HIV drug resistance (HIVDR) prevention and assessment strategy, developed by the World Health Organization (WHO) in partnership with HIVResNet, includes monitoring of HIVDR early warning indicators, surveys to assess acquired and transmitted HIVDR, and development of an accredited HIVDR genotyping laboratory network to support survey implementation in resource-limited settings. As of June 2011, 52 countries had implemented at least 1 element of the strategy, and 27 laboratories had been accredited. As access to antiretrovirals expands under the WHO/Joint United Nations Programme on HIV/AIDS Treatment 2.0 initiative, it is essential to strengthen HIVDR surveillance efforts in the face of increasing concern about HIVDR emergence and transmission.

Reference

DOI : 10.1093/cid/cis206
PMID : 22544182

M. R. Jordan,1,2 D. E. Bennett,3 M. A. Wainberg,4 D. Havlir,6 S. Hammer,6 C. Yang,3 L. Morris,7 M. Peeters,9,9 A. M. Wensing,10 N. Parkin,11 J. B. Nachega,12,13 A. Phillips,14 A. De Luca,15,16 E. Geng,5 A. Calmy,17,18 E. Raizes,3 P. Sandstrom,19 C. P. Archibald,19 J. Perriëns,1 C. M. McClure,1 S. Y. Hong,2 J. H. McMahon,2,20 N. Dedes,21 D. Sutherland,19 and S. Bertagnolio1

1World Health Organization, Geneva, Switzerland; 2Tufts University School of Medicine, Boston, Massachusetts; 3US Centers for Disease Control and Prevention, Atlanta, Georgia; 4McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Canada; 5University of California, San Francisco; 6Columbia University Medical Center, New York, New York; 7AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa; 8UMI 233 TransVHMI, Institut de Recherche pour le Développement, Montpellier, 9University of Montpellier 1, France; 10University Medical Center Utrecht, the Netherlands; 11Data First Consulting, Belmont, California; 12Stellenbosch University, Cape Town, South Africa; 13Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; 14University College London, United Kingdom; 15Institute of Clinical Infectious Diseases, Università Cattolica del Sacro Cuore, Rome, 16Division of Infectious Diseases, Siena University Hospital, Italy; 17Médecins sans Frontière Access Campaign, Geneva, 18Geneva University Hospital, Switzerland; 19Public Health Agency of Canada, Ottawa; 20Alfred Hospital, Melbourne, Australia; and 21International Treatment Preparedness Coalition, Bangkok, Thailand

The HIV drug resistance (HIVDR) prevention and assessment strategy, developed by the World Health Organization (WHO) in partnership with HIVResNet, includes monitoring of HIVDR early warning indicators, surveys to assess acquired and transmitted HIVDR, and development of an accredited HIVDR genotyping laboratory network to support survey implementation in resource-limited settings. As of June 2011, 52 countries had implemented at least 1 element of the strategy, and 27 laboratories had been accredited. As access to antiretrovirals expands under the WHO/Joint United Nations Programme on HIV/AIDS Treatment 2.0 initiative, it is essential to strengthen HIVDR surveillance efforts in the face of increasing concern about HIVDR emergence and transmission.

In 2010, 6.6 million adults and children in low- and middle-income countries received antiretroviral therapy (ART), representing a 22-fold increase from 2001 [1]. Successful ART scale-up in resource-limited settings (RLSs) was realized using a public health approach, including the use of standard protocols and simplified patient monitoring. The Joint United Nations Programme on HIV/AIDS and the World Health Organization (WHO) launched the Treatment 2.0 initiative in 2010, which is aimed at sustaining universal access to treatment and maximizing the preventive benefits of ART [2]. The treatment of millions of human immunodeficiency virus (HIV)–infected patients will inevitably be accompanied by the emergence and transmission of HIV drug resistance (HIVDR); moreover, the use of antiretroviral (ARV) drugs for prevention has the potential to increase the prevalence of HIVDR.

In high-income countries, HIVDR testing of individual patients is used to tailor regimen selection and predict treatment response. However, in most, if not all RLSs, HIVDR testing is neither routinely available nor recommended for individual patient management. Even with recent technological advancements, it is unlikely that HIVDR testing for patient care will be routinely available for millions of patients in the
HIVDR remains a threat to the long-term effectiveness of ARV treatment [4–8]. The absence of accessible HIVDR testing for individual patient care in RLSs necessitates that efforts be intensified to optimize population-based ARV treatment and to minimize HIVDR [9]. Unless carefully monitored and contained, HIVDR has the potential to reduce the efficacy of standard ART regimens in a high proportion of patients in RLSs.

**WORLD HEALTH ORGANIZATION HIVDR STRATEGY**

The WHO, in collaboration with HIVResNet, an advisory body of international experts from >50 institutions, has led global efforts for the prevention and assessment of HIVDR and has developed a standardized, minimum-resource, population-based strategy, which provides comparable data over time and across regions [10]. The strategy consists of 3 main assessment elements: HIVDR early warning indicators (EWIs) and surveys of acquired and transmitted HIVDR [10–12] for pediatric and adult populations. Additionally, the strategy includes the development of a network of HIVDR testing (genotyping) laboratories that support public health surveillance [13].

As of June 2011, 52 countries had implemented 1 or more elements of WHO’s HIVDR prevention and assessment strategy, and 27 laboratories had become members of the WHO HIVDR laboratory network [14] (Figure 1). The purpose of this supplement is to update the reader on global, regional, and country-level results generated by the strategy, as well as resulting public health actions. Additionally, this supplement reports a new surveillance method to assess HIVDR in children aged <18 months [15] and provides an update on the WHO external quality assurance process for genotyping, as well as WHO-supported operational research on the use of dried blood spots as specimens for HIVDR testing [16, 17].

**HIVDR EARLY WARNING INDICATORS**

The foundation of the global HIVDR prevention and assessment strategy is the annual monitoring of HIVDR EWIs at all ART clinics or representative clinics [10]. HIVDR EWIs assess prescribing practices, rates of retention, losses to follow-up, population-level adherence to ART, drug supply continuity, and virological suppression, which have been shown to be major predictors of HIV disease progression, death, and HIVDR [18–26]. Each EWI is associated with a suggested clinic-level target. The WHO HIVDR EWIs and their associated targets are listed in Table 1 of Bennett et al (in this supplement [27]). EWI results provide clinic and program managers with data about how their clinics perform compared with international targets aimed at preventing emergence of HIVDR [10]. To date, EWIs have been monitored in 50 countries, assessing >2000 clinics [27]. This supplement contains the first global EWI report with data obtained from 50 countries in 5 regions: Africa, Latin America and the Caribbean, Southeast Asia, the Western Pacific, and Eastern Europe. One regional report comes from Latin America and the Caribbean. A report comes from PharmAccess, which has implemented EWIs in 6 countries; additionally, 4 country reports come from China, Papua New Guinea, Vietnam, and Zimbabwe [27–33]. Although these data represent early experiences, common themes have emerged. The rate of patients lost to follow-up, rate of patient retention on first-line ART at 12 months, and patient adherence as measured by on-time pill pickup often fall below suggested targets and merit concern and investigation. Additionally, EWI monitoring in several countries has highlighted weaknesses in patient information systems that have resulted in the inability to monitor specific EWIs. Reported weaknesses in current data systems include incomplete records, missing data, use of nonstandardized records, and intraclinic and interclinic variability in data recording. As a result of EWI monitoring, several countries have taken steps to strengthen their information systems [27–31, 34, 35].

**SURVEYS OF ACQUIRED HIVDR**

WHO prospective surveys of acquired HIVDR are performed at sentinel ART clinics and supplement EWI data by estimating the prevalence and patterns of HIVDR in adult and pediatric populations experiencing ART failure [11]. At each sentinel survey clinic, a cohort is formed of patients initiating first-line ART. HIVDR genotyping is performed on patients initiating ART, and HIV RNA quantification is performed at the time that treatment is switched to second-line or 12 months after ART initiation for patients remaining on first-line treatment. In patients with detectable virus (>1000 copies/mL), genotyping is performed to characterize drug resistance mutations. Other survey endpoints include loss to follow-up, death, ART stop, or transfer to another ART clinic.

As of June 2011, 51 surveys of acquired HIVDR had been performed in 13 countries. The results from 12 surveys performed in 4 countries are published in this supplement [36–40]. The overall prevalence of HIVDR prior to the initiation of ART remains relatively low, and the predicted level of susceptibility observed among patients with HIVDR at 12 months suggests that the nucleoside reverse transcriptase inhibitor component of currently recommended second-line...
regimens, in combination with a boosted protease inhibitor, is likely to be effective for the majority surveyed [14]. Notably, in surveys published in this supplement, patient resistance to nonnucleoside reverse transcriptase inhibitors at the time of first-line ART initiation and treatment interruption are factors shown to predict virological failure at 12 months [36–39]. Additionally, surveys have concluded that improved adherence, especially among young adults, and improved defaulter tracing mechanisms may lead to improved rates of virological suppression and HIVDR prevention [36–39].

SURVEYS OF TRANSMITTED HIVDR

WHO TDR surveys use truncated sequential sampling and small sample sizes of ≤47 to classify TDR as low (<5%), high (>15%), or moderate (5%–15%) in populations likely to have been recently infected [12, 41]. Where possible, these surveys use remnant specimens and data from regularly performed serosurveys that estimate HIV prevalence, which are already in place in many RLSs. Results contribute to ART policy decisions, including guidelines on ART regimens and HIV prophylaxis.

As of June 2011, 53 TDR surveys have been performed in 22 countries [27]. Rates of TDR remain low in most areas and populations assessed using WHO-recommended methods [14]. However, as ART rollout continues, increased rates of TDR may occur. Recent publications, including reports published in this supplement, document moderate (5%–15%) levels of TDR in specific geographical regions [42–47]. These reports merit attention, warrant concern, and underscore the importance of routine TDR surveillance as well as addressing and preventing HIVDR at both national program and clinic levels.

NEW DIRECTIONS

Although monitoring of HIVDR EWIs are very important, their uptake has generally been limited to pilot experiences. Therefore, in 2011, WHO partnered with the Centers for Disease Control and Prevention (CDC) and the US President’s Emergency Plan for AIDS Relief (PEPFAR) to initiate a process that would update and simplify EWI guidance in order to facilitate monitoring at larger numbers of ART clinics. Simplifications of definitions and abstraction procedures are currently being considered that should facilitate integration into existing program monitoring and evaluation processes.

Additionally, in 2011, a less resource-intensive, cross-sectional survey using lot quality assurance sampling was developed to estimate acquired HIVDR. This cross-sectional...
survey should enable rapid generation of HIVDR data from large numbers of ART clinics using significantly smaller sample sizes than the current prospective method. Furthermore, this method will provide more comprehensive datasets describing HIVDR in adult and pediatric patients experiencing ART failure at both 12 and >24 months after treatment initiation. WHO and CDC/PEPFAR will pilot this new method in several countries in 2012, and the results of the pilot experience will be used to inform future global surveillance guidance.

As prevention of mother-to-child transmission is scaled up, fewer children are expected to become infected with HIV, but for those who do, a substantial proportion will be expected to harbor drug-resistant virus. Assessments of HIVDR in children <18 months of age are performed to guide population-level, first-line treatment in children. WHO and the CDC have developed a new surveillance protocol that uses remnant specimens from early infant diagnosis to make nationally representative statements about HIVDR in this population. This generic protocol is described in this supplement, and it will be piloted in Sub-Saharan Africa in 2012 by WHO and CDC/PEPFAR [15].

In conclusion, under the Treatment 2.0 initiative [2], millions of infected people will initiate or be maintained on ART. Additionally, many may be exposed to prevention strategies using ARVs. Now more than ever, greater funding, infrastructure and political will are urgently required to sustain and expand global HIVDR surveillance efforts. Without the benefit of cumulative standardized HIVDR surveillance data and a commitment on the part of international organizations, national governments, ART programs, funders, and implementing partners to identify and address programmatic challenges associated with HIVDR, we risk suboptimal population-level responses to current and future ART regimens over the next decade.

Notes

Acknowledgments. The authors sincerely acknowledge The Bill & Melinda Gates Foundation, which has generously funded the WHO Global HIVDR Strategy since 2007. The authors acknowledge the governments of Canada, Italy, and Spain, which have provided significant financial contributions leading to the success of WHO’s HIVDR prevention and assessment strategy. The authors acknowledge the contributions of the US CDC, PEPFAR, PharmAccess, Treat Asia, and the Agence National de Recherche sur le SIDA et les Hépatites for their strong support as implementing partners. The authors acknowledge the valuable contribution of Mark Myatt, Brixton Health, UK, to the development of the epidemiological and statistical methods used in the strategy. The authors acknowledge the contribution of Jesper Kjaer, Copenhagen HIV Program.

Disclaimer. Some authors are staff members of WHO or the CDC. The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions or stated policies of WHO or the CDC.

Financial support. This work was supported by grants from the National Institutes of Health (K23 AI074423-05 to M. R. J. and 5T32AI070438-19 to S. Y. H.) and the Lifespan/Tufts/Brown Center for AIDS Research (P30AI4853 to J. H. M.). The research leading to these results has received partial funding from the European Community’s Seventh Framework Programme (FP7/2007–2013) under the project “Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN)” (grant agreement No. 223131).

Supplement sponsorship. This article was published as part of a supplement entitled “The World Health Organization HIV Drug Resistance Prevention and Assessment Strategy: Global, Regional, and Country Progress,” sponsored by The Bill & Melinda Gates Foundation (38180).

Potential conflicts of interest. All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References


